|
Mammary Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
RASSF1A and RASSF2 have been shown to undergo promoter methylation at high frequency in primary lung and breast tumors and in brain metastases.
|
25482183 |
2014 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Promoter methylation status analysis of hereditary breast tumors revealed high methylation frequencies for the three genes (67% RASSF1A, 80% SLIT2, and 72% WIF1).
|
22315090 |
2013 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Little is known about the tumor-suppressive function of RASSF1A in breast tissue and whether its inactivation is mechanistically involved in the initiation and progression of breast tumors.
|
22266866 |
2012 |
|
Mammary Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
We have examined methylation status of the BRCA1, APC and RASSF1A promoter regions in a panel of 75 breast tumor and PB DNA samples from the same individual.
|
22129206 |
2011 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We showed that the methylation frequencies ranged from 19.6% (p16 ( INK4a )) to 87% (RASSF1A) in primary breast tumors of Tunisian patients.
|
19657672 |
2010 |
|
Mammary Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Methylation of RASSF1A promoter was observed in 1/31 (3.2%) non-cancerous breast tissues and 53/93 (57.0%) early stage breast tumors.
|
19374895 |
2009 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
LHGDN |
RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers.
|
18172292 |
2008 |
|
Mammary Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
LHGDN |
DNA methylation in benign breast epithelium in relation to age and breast cancer risk.
|
18483325 |
2008 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To evaluate epigenetic differences in tumor-related genes relating to ER and HER2/neu status of primary tumors, we examined the promoter methylation status of the promoter region CpG islands of eight major breast tumor-related genes (RASSF1A, CCND2, GSPT1, TWIST, APC, NES1, RARbeta2, and CDH1).
|
18485221 |
2008 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
RASSF1A was found to be methylated in 17 of 20 (85%) breast tumors; while sera from 15 of 20 (75%) of the patients showed concordant methylated RASSF1A, with a sensitivity of 88%.
|
17998817 |
2008 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
LHGDN |
High frequency of promoter hypermethylation of RASSF1A in tumorous and non-tumourous tissue of breast cancer.
|
16028839 |
2005 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
LHGDN |
Our data indicate that the mutant T-allele of RASSF1A at codon 133 is correlated with an increased number of breast tumors.
|
15942659 |
2005 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our data indicate that the mutant T-allele of RASSF1A at codon 133 is correlated with an increased number of breast tumors.
|
15942659 |
2005 |
|
Mammary Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
We conducted hypermethylation profiling of 151 primary breast tumors with association to known prognostic factors in breast cancer using methylation-specific PCR for six known tumor suppressor and related genes: RASSF1A, APC, TWIST, CDH1, GSTP1, and RAR-beta2.
|
15788661 |
2005 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
Prognostic DNA methylation marker in serum of cancer patients.
|
15251938 |
2004 |
|
Mammary Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
We examined the promoter methylation status of three normally unmethylated biologically significant cancer genes, RAS association domain family protein 1A (RASSF1A), adenomatous polyposis coli (APC), and death-associated protein kinase (DAP-kinase), by sensitive methylation-specific PCR in 34 breast tumor and paired preoperative serum DNA.
|
15448006 |
2004 |
|
Mammary Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
LHGDN |
The newly identified 3p21.3 tumour suppressor gene RASSF1A is methylated in the majority of primary lung tumours, lung tumour cell lines and in a variable percentage of breast tumours.
|
12527916 |
2003 |
|
Mammary Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
The newly identified 3p21.3 tumour suppressor gene RASSF1A is methylated in the majority of primary lung tumours, lung tumour cell lines and in a variable percentage of breast tumours.
|
12527916 |
2003 |
|
Mammary Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
The human Ras association domain family 1A (RASSF1A) gene, recently isolated from the lung and breast tumor suppressor locus 3p21.3, is highly methylated in primary lung, breast, nasopharyngeal and other tumors, and re-expression of RASSF1A suppresses the growth of several types of cancer cells.
|
14586413 |
2003 |
|
Mammary Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
LHGDN |
DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma.
|
14601057 |
2003 |
|
Mammary Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
The CpG island and promoter region of RASSF1A is highly methylated in primary lung and breast tumors.
|
11668500 |
2001 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To investigate RASSF1A as a candidate TSG for various cancers, we investigated: (a) RASSF1A methylation status in a large series of primary tumour and tumour lines; (b) chromosome 3p allele loss in lung tumours and (c) RASSF1 mutation analysis in breast tumours.
|
11313894 |
2001 |